The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 18, 2025

Filed:

Feb. 03, 2021
Applicants:

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Universite DE Montpellier, Montpellier, FR;

Inventors:

Pierre Roux, Saint Gely-du Fesc, FR;

Nikola Arsic, Montpellier, FR;

Gilles Gadea, Les Matelles, FR;

Philippe Fort, Castelnau-le-Lez, FR;

Fanny Tomas, Montpellier, FR;

Véronique Gire, Montpellier, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); C07K 14/47 (2006.01); C12N 5/095 (2010.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0695 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); C07K 14/4746 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); G01N 33/5073 (2013.01); G01N 33/57484 (2013.01); C12N 2501/998 (2013.01); C12N 2503/00 (2013.01); C12N 2506/30 (2013.01); C12N 2510/00 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/4748 (2013.01); G01N 2500/10 (2013.01);
Abstract

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.


Find Patent Forward Citations

Loading…